| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells.
|
Am J Pathol
|
2002
|
2.27
|
|
2
|
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
|
Cancer Res
|
2003
|
2.14
|
|
3
|
Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH.
|
Neoplasia
|
2006
|
1.98
|
|
4
|
Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment.
|
Cell Mol Life Sci
|
2011
|
1.62
|
|
5
|
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature.
|
Nat Methods
|
2005
|
1.32
|
|
6
|
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
|
Cancer Res
|
2011
|
1.28
|
|
7
|
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
|
Clin Cancer Res
|
2004
|
1.19
|
|
8
|
The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling.
|
EMBO Mol Med
|
2011
|
1.16
|
|
9
|
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
|
Clin Cancer Res
|
2002
|
1.09
|
|
10
|
An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients.
|
Oncogene
|
2004
|
1.07
|
|
11
|
Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2.
|
Blood
|
2003
|
1.07
|
|
12
|
Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts.
|
Mol Cancer Ther
|
2004
|
1.05
|
|
13
|
Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium.
|
BMC Genomics
|
2008
|
1.03
|
|
14
|
Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion.
|
Mol Cancer Res
|
2008
|
0.99
|
|
15
|
Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.
|
Front Oncol
|
2013
|
0.98
|
|
16
|
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy.
|
Mol Cancer Ther
|
2005
|
0.98
|
|
17
|
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
|
Clin Cancer Res
|
2003
|
0.96
|
|
18
|
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain.
|
Int J Biochem Cell Biol
|
2007
|
0.95
|
|
19
|
Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.
|
Cancer Res
|
2003
|
0.95
|
|
20
|
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.
|
J Biol Chem
|
2010
|
0.94
|
|
21
|
The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
|
Clin Cancer Res
|
2006
|
0.93
|
|
22
|
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
|
Mol Cancer Ther
|
2012
|
0.92
|
|
23
|
Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development.
|
Eur J Cancer
|
2006
|
0.92
|
|
24
|
Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells.
|
Cancer Res
|
2009
|
0.92
|
|
25
|
A complex of α6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6.
|
EMBO Mol Med
|
2012
|
0.91
|
|
26
|
Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles.
|
J Med Chem
|
2009
|
0.90
|
|
27
|
Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts.
|
Cancer Res
|
2012
|
0.90
|
|
28
|
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
|
Neoplasia
|
2009
|
0.89
|
|
29
|
Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging.
|
PLoS One
|
2013
|
0.88
|
|
30
|
A proteomic approach for the identification of vascular markers of liver metastasis.
|
Cancer Res
|
2009
|
0.87
|
|
31
|
Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells.
|
Eur J Cancer
|
2008
|
0.87
|
|
32
|
Potential antagonism of tubulin-binding anticancer agents in combination therapies.
|
Clin Cancer Res
|
2005
|
0.85
|
|
33
|
A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies.
|
Histochem Cell Biol
|
2010
|
0.85
|
|
34
|
Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
|
Int J Cancer
|
2014
|
0.84
|
|
35
|
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice.
|
Thromb Haemost
|
2004
|
0.84
|
|
36
|
The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.
|
J Urol
|
2010
|
0.84
|
|
37
|
Targeting angiogenesis with compounds from the extracellular matrix.
|
Int J Biochem Cell Biol
|
2011
|
0.84
|
|
38
|
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
|
Mol Cancer Ther
|
2013
|
0.83
|
|
39
|
Interleukin-1β regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1α.
|
Eur J Cancer
|
2010
|
0.82
|
|
40
|
Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.
|
Neoplasia
|
2012
|
0.82
|
|
41
|
Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype.
|
Clin Exp Metastasis
|
2009
|
0.82
|
|
42
|
Solution state conformation and degradation of cyclopeptides containing an NGR motif.
|
J Pept Sci
|
2005
|
0.80
|
|
43
|
Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.
|
Thromb Haemost
|
2011
|
0.80
|
|
44
|
Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.
|
Cancer Chemother Pharmacol
|
2013
|
0.79
|
|
45
|
Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.
|
Pigment Cell Melanoma Res
|
2014
|
0.79
|
|
46
|
Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery.
|
Histochem Cell Biol
|
2011
|
0.78
|
|
47
|
In vivo measurement of vascular modulation in experimental tumors using a fluorescent contrast agent.
|
Photochem Photobiol
|
2008
|
0.78
|
|
48
|
Dual targeting of tumor and endothelial cells by gonadotropin-releasing hormone agonists to reduce melanoma angiogenesis.
|
Endocrinology
|
2010
|
0.77
|
|
49
|
Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.
|
J Pathol
|
2009
|
0.77
|
|
50
|
Glycerophosphoinositols inhibit the ability of tumour cells to invade the extracellular matrix.
|
Eur J Cancer
|
2005
|
0.76
|
|
51
|
IDN 5390: a new concept in taxane development.
|
Anticancer Drugs
|
2003
|
0.76
|
|
52
|
Inactivating STAT3: bad for tumor, good for muscle.
|
Cell Cycle
|
2015
|
0.75
|
|
53
|
Vascular endothelium summary statement III: Cancer prevention and control.
|
Vascul Pharmacol
|
2006
|
0.75
|
|
54
|
Correction: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.
|
Oncotarget
|
2016
|
0.75
|